Skip to content
Clinical Trials – home
Systimmune Inc.
Sponsor

Systimmune Inc.

United States 15318 Northeast 95th Street, 98052-2517, United States

About the sponsor

Clinical research activity is centered on cancer, with attention to advanced solid tumors and metastatic disease. The sponsor’s trial portfolio reflects interest in difficult-to-treat malignancies, including non-small cell lung cancer and other solid tumors.

  • Non-small cell lung cancer
  • Metastatic solid tumors
  • Unresectable malignancies
  • Anticancer therapeutics

Research sites across multiple countries support the evaluation of therapies aimed at tumor control in advanced disease settings.

About Specializations

Systimmune Inc. runs clinical trials in conditions such as Transitional cell carcinoma, Transitional cell carcinoma metastatic, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

1 clinical trial

Transitional cell carcinoma+1

Not yet recruiting

Phase 3 Study of trastuzumab brengitecan versus platinum‑based chemotherapy in adults with HER2‑positive metastatic urothelial cancer after anti‑PD‑(L)1 therapy

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Systimmune Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.